← FDA DRUG APPROVALS

FDA ANDA · ANDA205685

TOBRAMYCIN SULFATE

Sponsor: XELLIA PHARMS APS

APPLICATION
ANDA205685
TYPE
ANDA
ORIGINAL APPROVAL
2014-09-16
LATEST ACTION
2025-05-30
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

TOBRAMYCIN SULFATEPrescription
TOBRAMYCIN SULFATE EQ 1.2GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

2025-05-30Labeling · Supplement 3 · standardAP
2023-02-10Labeling · Supplement 1 · standardAP
2014-09-16UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →